Zcash Awards $8 Million in Grants After Orchard Bug Crisis 
Nike Stock Slides as Revenue Miss Clouds Turnaround 
Trump Praises Boeing 737 Max After Flydubai Crash Attempt 
Coinbase, Circle Stocks Slide as Bank Group Sues OCC Over Crypto Charters 
Ripple Locks 700 Million XRP Back in Escrow After October Release 
Robinhood Stock Nears $114 as Jobs Data Boosts Risk Appetite 
Lynas Shares Slide on A$968 Million Meteoric Resources Deal 
Evernorth Set for Nasdaq Debut With 473 Million XRP Treasury 
Flydubai Co-Pilot Tried to Crash Israel-Bound Jet, Netanyahu Says 
WordPress Malware Uses Ethereum to Evade Removal 
Citi Raises Bitcoin Target to $113,000 as Crypto Outlook Improves 
Bank of America Sees EUR/USD at 1.15 by Year-End 
Goldman Sachs Names CATL, Zenergy Top China Battery Picks 
Sanofi, Regeneron Expand Drug Partnership in $8 Billion Deal 
XRP Ledger Hits 10 Million AI Payments as Bitcoin Retreats 
SoftBank Shares Fall After $10 Billion OpenAI Investment 
Add as a preferred source on Google
UTRECHT, The Netherlands, Aug. 09, 2017 -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will present a company overview at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16, 2017 at 9:45 a.m. ET.
A live webcast of the presentation will be available on the Investors page of the Company's website, http://www.merus.nl. An archived presentation will be available for 90 days.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus’ lead bispecific antibody candidate, MCLA-128, is expected to begin a Phase 2 combination trial in the second half of 2017 in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in Europe in gastric, ovarian, endometrial and non-small cell lung cancers. Merus’ second bispecific antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, as well as MCLA-145 designed to bind to PD-L1 and a non-disclosed second immunomodulatory target, which is being developed in collaboration with Incyte Corporation.
Contacts: Media: Eliza Schleifstein +1 973 361 1546 [email protected] Investors: Kimberly Minarovich +1 646 368 8014 [email protected]
